Drugs / RTX-240
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04372706 | May 2020 → Nov 2022 | acute myeloid leukemia | Rubius Therapeutics | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RTX-240 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04372706 ↗ |
| Action | Activate | “with the goal of stimulating the innate and adaptive immune systems” NCT04372706 ↗ |
| Modality | Cell therapy | “RTX-240 is a cellular therapy” NCT04372706 ↗ |